These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1069 related items for PubMed ID: 9816034

  • 1. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN.
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [Abstract] [Full Text] [Related]

  • 2. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [Abstract] [Full Text] [Related]

  • 3. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z, Champlin R, Rondon G, Frye D, Valero V, Mehra R, Hortobagyi G.
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [Abstract] [Full Text] [Related]

  • 4. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD, Jolivet J, Birch R, Hopkins LG, Greco FA.
    Cancer; 1997 Feb 15; 79(4):740-8. PubMed ID: 9024712
    [Abstract] [Full Text] [Related]

  • 5. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
    Greco FA, Hainsworth JD.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, Lembersky BC, Mamounas EP.
    Clin Breast Cancer; 2002 Dec 15; 3(5):333-40. PubMed ID: 12533263
    [Abstract] [Full Text] [Related]

  • 7. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
    Bontenbal M, Creemers GJ, Braun HJ, de Boer AC, Janssen JT, Leys RB, Ruit JB, Goey SH, van der Velden PC, Kerkhofs LG, Schothorst KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C, Dutch Community Setting Trial for the Clinical Trial Group.
    J Clin Oncol; 2005 Oct 01; 23(28):7081-8. PubMed ID: 16192591
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ, Thomssen C, du Bois A, Untch M, Lisboa B, Köhler G, Diergarten K.
    Semin Oncol; 1997 Oct 01; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [Abstract] [Full Text] [Related]

  • 9. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A, Extra JM, Espié M, Cuvier C, Marty M.
    In Vivo; 1998 Oct 01; 12(5):559-62. PubMed ID: 9827368
    [Abstract] [Full Text] [Related]

  • 10. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S, Tucci A, Villani G, Carteni G, Spadini N, Palumbo R.
    Anticancer Res; 2000 Oct 01; 20(1B):485-91. PubMed ID: 10769710
    [Abstract] [Full Text] [Related]

  • 11. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P, Gehl J, Boesgaard M, Jensen TP, Jensen BV.
    Semin Oncol; 1996 Feb 01; 23(1 Suppl 1):13-8. PubMed ID: 8629030
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
    D'Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD.
    Clin Cancer Res; 1999 Feb 01; 5(2):275-9. PubMed ID: 10037175
    [Abstract] [Full Text] [Related]

  • 13. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME, Clemons MJ, Provencher L, Panasci L, Yelle L, Rayson D, Latreille J, Vandenberg T, Goel R, Zibdawi L, Rahim Y, Pouliot JF.
    J Clin Oncol; 2009 Dec 10; 27(35):5906-10. PubMed ID: 19858391
    [Abstract] [Full Text] [Related]

  • 14. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
    Costanza ME, Berry D, Henderson IC, Ratain MJ, Wu K, Shapiro C, Duggan D, Kalra J, Berkowitz I, Lyss AP.
    Clin Cancer Res; 1995 Jul 10; 1(7):699-704. PubMed ID: 9816035
    [Abstract] [Full Text] [Related]

  • 15. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
    Dombernowsky P, Gehl J, Boesgaard M, Jensen TP, Jensen BW, Ejlertsen B.
    Semin Oncol; 1995 Dec 10; 22(6 Suppl 15):13-7. PubMed ID: 8643964
    [Abstract] [Full Text] [Related]

  • 16. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
    Blajman C, Balbiani L, Block J, Coppola F, Chacon R, Fein L, Bonicatto S, Alvarez A, Schmilovich A, Delgado FM.
    Cancer; 1999 Mar 01; 85(5):1091-7. PubMed ID: 10091793
    [Abstract] [Full Text] [Related]

  • 17. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
    Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN.
    Clin Cancer Res; 2002 Nov 01; 8(11):3360-8. PubMed ID: 12429622
    [Abstract] [Full Text] [Related]

  • 18. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Klein JL, Rey PM, Dansey RD, Karanes C, Du W, Abella E, Cassells L, Hamm C, Peters WP, Baynes RD.
    Bone Marrow Transplant; 2000 May 01; 25(10):1047-52. PubMed ID: 10828864
    [Abstract] [Full Text] [Related]

  • 19. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T, Jagiello-Gruszfeld A.
    Int J Clin Pharmacol Res; 2001 May 01; 21(3-4):111-7. PubMed ID: 12067140
    [Abstract] [Full Text] [Related]

  • 20. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
    Mikhak B, Zahurak M, Abeloff MD, Fetting JH, Davidson NE, Donehower RC, Waterfield W, Kennedy MJ.
    Cancer; 1999 Feb 15; 85(4):899-904. PubMed ID: 10091768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.